Key result
Mendelian randomization indicated that down-regulation of IL-6R signaling and Lp(a) independently reduce cardiovascular disease risk.
Why the study?
Does down-regulation of IL-6R signaling and Lp(a) independently reduce CVD risk?
Observational
Does down-regulation of IL-6R signaling and Lp(a) independently reduce CVD risk?
Down-regulation of IL-6R signaling and Lp(a) independently reduce cardiovascular disease risk, suggesting complementary therapeutic targets for CVD risk mitigation.
In the study at hand, 2-sample Mendelian randomization supported a causal effect of interleukin-6 receptor (IL-6R) signaling on Lp(a) concentrations, revealing a direct interplay between 2 causal risk factors for cardiovascular disease (CVD). Importantly, epidemiological analyses in UK Biobank showed that neglecting the IL-6R functional state can confound the association between IL-6 levels and Lp(a). However, the effect of circulating IL-6 on Lp(a) concentrations was modest even when the functional state of the receptor was considered. In line, factorial Mendelian randomization indicated that down-regulation of IL-6R signaling and Lp(a) independently reduce CVD risk, highlighting complementary opportunities for CVD risk mitigation.
No takes yet. Share an insight, caveat, or question.
Kheirkhah et al. (2026) conducted an observational in Cardiovascular disease. Interleukin-6 receptor (IL-6R) signaling and Lp(a) was evaluated on Cardiovascular disease risk and Lp(a) concentrations. Mendelian randomization indicated that down-regulation of IL-6R signaling and Lp(a) independently reduce cardiovascular disease risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: